Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2005 May;89(5):639-40.
doi: 10.1136/bjo.2004.053058.

Disappearance of eyelid xanthelasma following oral simvastatin (Zocor)

C L Shields, A Mashayekhi, J A Shields, P Racciato
Case Reports

Disappearance of eyelid xanthelasma following oral simvastatin (Zocor)

C L Shields et al. Br J Ophthalmol. 2005 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
A 68 year old man with hypertension and elevated cholesterol and bilateral upper and lower eyelid xanthelasma. He was on oral simvastatin for hypercholesterolaemia. (A) January 1992. At presentation, the multifocal yellow xanthelasma are noted. (B) April 2002. After 10 years lost to ophthalmic follow up, the patient returned with complete resolution of xanthelasma.
See this image and copyright information in PMC

References

    1. Farmer JA, Gotto AM Jr. The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 2003;3:3i–9i. - PubMed
    1. Shields JA, Shields CL. Atlas of eyelid and conjunctival tumors. Philadelphia: Lippincott Williams & Wilkins, :138–9.
    1. Rohrich RJ, Janis JE, Pownell PH. Xanthelasma palpebrarum: a review and current management principles. Plast Reconstr Surg 2002;110:1310–14. - PubMed
    1. Segal P, Insull W Jr, Chambless LE, et al. The association of dyslipoproteinemia with corneal arcus and xanthelasma. The Lipid Research Clinics Program Prevalence Study. Circulation 1986;73:108–18. - PubMed
    1. Dumont JM. Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis: design, baseline characteristics, and progress of the Multicenter Anti-Atheroma Study (MAAS). Control Clin Trials 1993;14:209–28. - PubMed